sb 239063 has been researched along with interleukin-8 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, JL; Bochnowicz, S; Griswold, DE; Hay, DW; Lee, JC; Osborn, RR; Rieman, DJ; Romanic, AM; Underwood, DC; Webb, EF | 1 |
| Barnes, PJ; Donnelly, LE; Fenwick, PS; Finney-Hayward, TK; Giembycz, MA; Higgins, LS; Kirschenbaum, F; Nicholson, AG; Smith, SJ | 1 |
| Gong, W; Holden, NS; King, EM; Newton, R; Rider, CF | 1 |
3 other study(ies) available for sb 239063 and interleukin-8
| Article | Year |
|---|---|
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Topics: Animals; Bleomycin; Cells, Cultured; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Guinea Pigs; Humans; Hypertension, Pulmonary; Imidazoles; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-6; Interleukin-8; Lipopolysaccharides; Lung; Lung Diseases, Obstructive; Male; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinases; Neutrophils; p38 Mitogen-Activated Protein Kinases; Pulmonary Alveoli; Pulmonary Fibrosis; Pyrimidines; Rats; Rats, Inbred Lew; Sialoglycoproteins; Tumor Necrosis Factor-alpha | 2000 |
Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.
Topics: Blotting, Western; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Indoles; Interleukin-8; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinase 14; Monocytes; Pneumonia; Protein Kinase Inhibitors; Pyrimidines; RNA Stability; Tumor Necrosis Factor-alpha | 2006 |
Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK.
Topics: Blotting, Western; Cell Line; Cell Line, Tumor; Cycloheximide; Dactinomycin; Dexamethasone; Dose-Response Relationship, Drug; Dual Specificity Phosphatase 1; Enzyme Inhibitors; Gene Expression Regulation; Glucocorticoids; Humans; Imidazoles; Interleukin-8; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2009 |